Abstract
Our previous experimental studies have shown that the best approach to increase the biological anti-tumour activity of interleukin 2 (IL-2) is not co-administration of another cytokine, but the association with immunomodulating neurohormones, in an attempt to reproduce the physiological links between psychoendocrine and immune systems, which play a fundamental role in the regulation of the immune responses. In particular, the association with the pineal neurohormone melatonin (MLT) has been shown to cause tumour regressions in neoplasms that are generally non-responsive to IL-2 alone. To confirm these preliminary results, a clinical trial was performed in locally advanced or metastatic patients with solid tumours other than renal cell cancer and melanoma. The study included 80 consecutive patients, who were randomised to be treated with IL-2 alone subcutaneously (3 million IU day-1 at 8.00 p.m. 6 days a week for 4 weeks) or IL-2 plus MLT (40 mg day-1 orally at 8.00 p.m. every day starting 7 days before IL-2). A complete response was obtained in 3/41 patients treated with IL-2 plus MLT and in none of the patients receiving IL-2 alone. A partial response was achieved in 8/41 patients treated with IL-2 plus MLT and in only 1/39 patients treated with IL-2 alone. Tumour objective regression rate was significantly higher in patients treated with IL-2 and MLT than in those receiving IL-2 alone (11/41 vs 1/39, P < 0.001). The survival at 1 year was significantly higher in patients treated with IL-2 and MLT than in the IL-2 group (19/41 vs 6/39, P < 0.05). Finally, the mean increase in lymphocyte and eosinophil number was significantly higher in the IL-2 plus MLT group than in patients treated with IL-2 alone; on the contrary, the mean increase in the specific marker of macrophage activation neopterin was significantly higher in patients treated with IL-2 alone. The treatment was well tolerated in both groups of patients. This study shows that the concomitant administration of the pineal hormone MLT may increase the efficacy of low-dose IL-2 subcutaneous therapy.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Atzpodien J., Kirchner H. Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms. Klin Wochenschr. 1990 Jan 4;68(1):1–11. doi: 10.1007/BF01648882. [DOI] [PubMed] [Google Scholar]
- Broder S., Muul L., Waldmann T. A. Suppressor cells in neoplastic disease. J Natl Cancer Inst. 1978 Jul;61(1):5–11. doi: 10.1093/jnci/61.1.5. [DOI] [PubMed] [Google Scholar]
- Denicoff K. D., Durkin T. M., Lotze M. T., Quinlan P. E., Davis C. L., Listwak S. J., Rosenberg S. A., Rubinow D. R. The neuroendocrine effects of interleukin-2 treatment. J Clin Endocrinol Metab. 1989 Aug;69(2):402–410. doi: 10.1210/jcem-69-2-402. [DOI] [PubMed] [Google Scholar]
- Dillman R. O., Oldham R. K., Tauer K. W., Orr D. W., Barth N. M., Blumenschein G., Arnold J., Birch R., West W. H. Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial. J Clin Oncol. 1991 Jul;9(7):1233–1240. doi: 10.1200/JCO.1991.9.7.1233. [DOI] [PubMed] [Google Scholar]
- Grimm E. A., Mazumder A., Zhang H. Z., Rosenberg S. A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982 Jun 1;155(6):1823–1841. doi: 10.1084/jem.155.6.1823. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lissoni P., Barni S., Archili C., Cattaneo G., Rovelli F., Conti A., Maestroni G. J., Tancini G. Endocrine effects of a 24-hour intravenous infusion of interleukin-2 in the immunotherapy of cancer. Anticancer Res. 1990 May-Jun;10(3):753–757. [PubMed] [Google Scholar]
- Lissoni P., Barni S., Ardizzoia A., Brivio F., Tancini G., Conti A., Maestroni G. J. Immunological effects of a single evening subcutaneous injection of low-dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients. J Biol Regul Homeost Agents. 1992 Oct-Dec;6(4):132–136. [PubMed] [Google Scholar]
- Lissoni P., Barni S., Rovelli F., Brivio F., Ardizzoia A., Tancini G., Conti A., Maestroni G. J. Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results. Eur J Cancer. 1993;29A(2):185–189. doi: 10.1016/0959-8049(93)90170-k. [DOI] [PubMed] [Google Scholar]
- Lissoni P., Tisi E., Brivio F., Barni S., Rovelli F., Perego M., Tancini G. Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2. Eur J Cancer. 1991;27(8):1014–1016. doi: 10.1016/0277-5379(91)90271-e. [DOI] [PubMed] [Google Scholar]
- Maestroni G. J., Conti A., Pierpaoli W. Role of the pineal gland in immunity. Circadian synthesis and release of melatonin modulates the antibody response and antagonizes the immunosuppressive effect of corticosterone. J Neuroimmunol. 1986 Nov;13(1):19–30. doi: 10.1016/0165-5728(86)90047-0. [DOI] [PubMed] [Google Scholar]
- Ritchie A. W., Oswald I., Micklem H. S., Boyd J. E., Elton R. A., Jazwinska E., James K. Circadian variation of lymphocyte subpopulations: a study with monoclonal antibodies. Br Med J (Clin Res Ed) 1983 Jun 4;286(6380):1773–1775. doi: 10.1136/bmj.286.6380.1773. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stein R. C., Malkovska V., Morgan S., Galazka A., Aniszewski C., Roy S. E., Shearer R. J., Marsden R. A., Bevan D., Gordon-Smith E. C. The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2 [corrected]. Br J Cancer. 1991 Feb;63(2):275–278. doi: 10.1038/bjc.1991.64. [DOI] [PMC free article] [PubMed] [Google Scholar]
- West W. H. Continuous infusion recombinant interleukin-2 (rIL-2) in adoptive cellular therapy of renal carcinoma and other malignancies. Cancer Treat Rev. 1989 Jun;16 (Suppl A):83–89. doi: 10.1016/0305-7372(89)90027-3. [DOI] [PubMed] [Google Scholar]